Previous 10 | Next 10 |
home / stock / mrk / mrk articles
The Delaware Supreme Court reportedly ruled in favor of Bayer AG (OTC: BAYRY) (OTC: BAYZF), stating that the company is not accountable f...
Tesla, Inc. (NASDAQ:TSLA) shares have been going through a lean phase and the modest recovery seen has been in fits-and-starts. Against this backdr...
The FDA's Pulmonary-Allergy Drugs Advisory Committee will convene Friday to discuss Merck & Co Inc's (NYSE: MRK) ma...
Johannes Oosthuizen, President at Merck & Co (NYSE:MRK), reported a large insider sell on November 13, according to a new SEC filing. What Hap...
The Nasdaq 100 closed lower by more than 100 points on Thursday. Investors, meanwhile, focused on some notable insider trades. When insiders sell s...
BioXcel Therapeutics Inc (NASDAQ: BTAI) announced overall survival (OS) data from its Phase 2 trial of BXCL701 in combination with Merck ...
As trading for November begins, Mizuho recommends a few stocks for investors to consider. The Dow Jones, S&P 500, and Nasdaq Composite have all...
The FDA approved Merck & Co Inc's (NYSE: MRK) Keytruda, in combination with gemcitabine and cisplatin, for locally advanced unres...
In the current session, the stock is trading at $103.50, after a 0.78% increase. Over the past month, Merck & Co Inc. (NYSE:MRK) stock increase...
News, Short Squeeze, Breakout and More Instantly...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.77 per share of the company’s common stock for the fourth quarter of 2024. Payment will be made on Oct. 7, 2024, to shareholders of r...
2024-07-23 09:30:00 ET The Dow Jones Industrial Average has long been a bellwether for the overall health of the U.S. stock market, tracking 30 large publicly owned companies across various sectors. While the index has seen modest gains in 2024, one of its constituents has been signific...
Clesrovimab met all primary safety and efficacy endpoints Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from its Phase 2b/3 clinical trial (MK-1654-004) evaluating clesrovimab (MK-1654), the company’s investigati...